Drug repurposing and new drug targets: perspectives for novel treatment options in mental health disorders

Berend Malchow¹, Jens Wiltfang^{2

3

4}

Affiliations

¹ Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, Goettingen, Germany. berend.malchow@med.uni-goettingen.de.
² Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, Goettingen, Germany.
³ German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany.
⁴ Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, Aveiro, Portugal.

Editorial

Berend Malchow et al. J Neural Transm (Vienna). 2023 Aug.

. 2023 Aug;130(8):987-988.

doi: 10.1007/s00702-023-02671-0. Epub 2023 Jul 15.

Berend Malchow¹, Jens Wiltfang^{2

3

4}

¹ Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, Goettingen, Germany. berend.malchow@med.uni-goettingen.de.
² Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, Goettingen, Germany.
³ German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany.
⁴ Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, Aveiro, Portugal.

No abstract available

References

1. Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3:673–683 (PMID: 15286734) - DOI - PubMed
1. Breckenridge A (2019) Overcoming the legal and regulatory barriers to drug repurposing. Nat Rev Drug Discov 18(1):1–2 (PMID: 29880920) - DOI - PubMed
1. Vatansever S, Schlessinger A, Wacker D, Kaniskan HÜ, Jin J, Zhou MM (2021) Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: State-of-the-arts and future directions. Med Res Rev 41(3):1427–1473 (PMID: 33295676) - DOI - PubMed